Related Experiment Video
Updated: Aug 13, 2026
High-throughput Screening of Chemical Compounds to Elucidate Their Effects on Bacterial Persistence
Published on: February 23, 2021
Clinical experience with parenteral and oral ofloxacin in severe infections
K Kanellakopoulou1, H Giamarellou
1First Department of Propedeutic Medicine, Athens University School of Medicine, Laiko, General Hospital, Greece.
Abstract:
This study included 107 patients who were given ofloxacin at daily doses of 400-800 mg for 10 days to 12 months for treatment of a variety of infections. 77 patients were given ofloxacin orally and 30 received it intravenously. Infections treated were bronchopneumonia (29), chronic bronchitis with acute exacerbation (15), chronic osteomyelitis with exacerbation (20), soft tissue infections (13), complicated urinary tract infections (7), chronic prostatis with exacerbation (7), malignant external otitis (4), or other infections (12). Pathogens included Pseudomonas aeruginosa (39), Acinetobacter spp. (9), various Enterobacteriaceae (30), Haemophilus influenzae (26), pneumococci (1) and Staphylococcus aureus (4). MICs of ofloxacin ranged from less than 0.06-2 mg/l. Clinically, 69% of the patients were cured, 18% improved and 13% failed to respond. Bacteriologically, pathogens were eradicated in 70%, persisted in 16% and relapsed in 14%. Resistance during therapy developed almost exclusively in P. aeruginosa strains (17.9%). The following adverse reactions were reported: gastrointestinal disturbances (6), rash plus facial oedema (1), abnormal liver function tests (5) and leukopenia (1). It is concluded that ofloxacin is suitable for treatment of a variety of infections, ranging from serious life threatening infections in ICU patients to chronic ones that require prolonged therapy.
Insights
Ofloxacin effectively treated various infections in 107 patients, showing high cure rates. This fluoroquinolone antibiotic demonstrated efficacy in both oral and intravenous administration for diverse bacterial pathogens.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Ofloxacin is a broad-spectrum fluoroquinolone antibiotic.
- Bacterial infections pose significant therapeutic challenges, necessitating effective antimicrobial agents.
- Assessing the clinical utility of ofloxacin in diverse infections is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of ofloxacin in treating a wide range of bacterial infections.
- To determine clinical and bacteriological outcomes.
- To monitor the development of antimicrobial resistance and adverse events.
Main Methods:
- A study involving 107 patients treated with ofloxacin (400-800 mg daily) orally or intravenously.
- Infections included bronchopneumonia, chronic bronchitis, osteomyelitis, soft tissue infections, UTIs, prostatitis, and malignant external otitis.
- Pathogens identified were Pseudomonas aeruginosa, Acinetobacter spp., Enterobacteriaceae, Haemophilus influenzae, pneumococci, and Staphylococcus aureus.
Main Results:
- Clinical cure was achieved in 69% of patients, with 18% showing improvement.
- Bacteriological eradication occurred in 70% of cases; resistance developed primarily in Pseudomonas aeruginosa (17.9%).
- Adverse reactions were generally mild, including gastrointestinal disturbances and abnormal liver function tests.
Conclusions:
- Ofloxacin is effective for treating various infections, including serious and chronic conditions.
- The antibiotic demonstrated a favorable clinical and bacteriological response profile.
- Ofloxacin is a suitable therapeutic option for a broad spectrum of bacterial infections.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:17Urinary Tract Infection IV: Nursing Management
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:28Inhibitors of Bacterial DNA Synthesis
01:25Clinical Significance of Antibiotic Resistance